Regeneron is off and running with its launch of linvoseltamab in Europe. In the U.S., the company is awaiting an FDA decision after last year’s rejection. More: Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J
read moreWith an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. Playing defense, ImmunityBio is touting its Anktiva combo’s unique duration of response performance. More: As J&J aims to 'fundamentally change' how bladder
read moreAkeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in its partner Summit Therapeutics aren’t taking the result too well. More: Summit stock crashes as Akeso shares
read moreAmgen is plugging $900 million into an expansion of its biomanufacturing facility in New Albany, Ohio. The project is expected to bring the total number of Amgen jobs in the state to 750 and increase the company’s overall investment in
read moreAbbVie aims to invest $10 billion in the U.S. through 2035 to support its current growth plans and expand into new areas like obesity, the company’s CEO, Rob Michael, said on a call Friday. More: Following pharma's tariff trend, AbbVie
read more
Cambridge firm in-licenses two oncology programmes More: Mosaic therapeutics expands pipeline with Astex deal Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals